Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus*

Frank Dörje^{1,**}, Thomas Friebe¹, Reinhold Tacke², Ernst Mutschler¹, and Günter Lambrecht¹

¹ Department of Pharmacology, University of Frankfurt, Theodor-Stern-Kai 7, Gebäude 75A, D-6000 Frankfurt/M., Federal Republic of Germany

² Institute of Inorganic Chemistry, University of Karlsruhe, Engesserstrasse, D-7500 Karlsruhe, Federal Republic of Germany

Received January 22, 1990/Accepted April 5, 1990

Summary. The present study was designed to further characterize the muscarinic receptors mediating contraction of the guinea-pig uterus. The affinities of various selective muscarinic antagonists were determined and compared with those obtained at M1 (rabbit vas deferens), M₂ (guinea-pig atria) and M₃ receptors (guinea-pig ileum).

The contractile responses of uterine smooth muscle from immature guinea-pigs to carbachol ($pD_2 = 5.73$) were competitively antagonized by pirenzepine $(pA_2 =$ 7.04), AF-DX 116 (11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzo. diazepin-6-one) $(pA_2 = 6.96)$, himbacine $(pA_2 = 7.92)$, methoctramine ($pA_2 = 7.52$), 4-DAMP (4-diphenylacetoxy-N-methylpiperidine methiodide) $(pA_2 = 8.87)$ and sila-hexocyclium ($pA_2 = 8.81$). A comparison of affinity values indicates that the muscarinic receptors present in guinea-pig uterus display a novel pharmacological profile which is not consistent with the presence of either an M_1 , M₂ or M₃ receptor. The affinities determined for the different antagonists rather showed a close similarity to those obtained at muscarinic receptors present in rat striatum and NG108-15 cells which are considered pharmacological equivalents (M_4 receptors) of the m4 gene product. We thus hypothesize that the guinea-pig isolated uterus preparation may serve as a simple functional assay system to study the pharmacology of M_4 receptors.

Key words: Muscarinic receptors - M₄ receptors -Guinea-pig uterus - Pirenzepine - Methoctramine -Sila-hexocyclium

Send offprint requests to F. Dörje at the present address

Introduction

Radioligand binding as well as in vitro and in vivo functional studies have revealed the existence of at least three pharmacologically distinct muscarinic receptor subtypes, which have been termed M_1 , M_2 and M_3 (Doods et al. 1987; Mitchelson 1988; Levine and Birdsall 1989). M₁ receptors are mainly present in neuronal tissues (e.g. autonomic ganglia, cerebral cortex and hippocampus) and are characterized by a high affinity for pirenzepine (affinity profile $M_1 > M_3 \ge M_2$) (Hammer et al. 1980; Hammer and Giachetti 1982). M₂ and M₃ receptors are primarily found in lower brain areas and in peripheral effector organs such as heart (M_2) , smooth muscle (M_3) and glands (M_3) and display low affinity for pirenzepine. They can be distinguished by the use of selective antagonists such as methoctramine and AF-DX 116 $(M_2 > M_1 > M_3)$ (Melchiorre et al. 1987; Waelbroeck et al. 1989; Hammer et al. 1986; Micheletti et al. 1987), himbacine $(M_1 \approx M_2 > M_3)$ (Gilani and Cobbin 1986; Lazareno and Roberts 1989), sila-hexocyclium (M1 \geq M₃ > M₂) (Eltze et al. 1988; Waelbroeck et al. 1989), 4-DAMP and hexahydro-sila-difenidol $(M_3 \ge M_1 > M_2)$ (Barlow et al. 1976; Mutschler and Lambrecht 1984; Lambrecht et al. 1989).

The pharmacology of the M_1 , M_2 and M_3 receptors closely corresponds to that of the m1, m2 and m3 receptor subtypes, respectively, identified by recent receptor cloning studies (Akiba et al. 1988; Buckley et al. 1989). Recombinant DNA technology has also revealed the existence of two additional muscarinic receptor subtypes, m4 and m5, whose pharmacology has not been studied in detail so far (Bonner et al. 1987, 1988; Peralta et al. 1987).

Recently, Eglen et al. (1989) suggested that the contractile response to carbachol in the guinea-pig estrogendominated uterus is mediated by a homogenous population of M_2 receptors. As smooth muscle contraction is usually mediated by M3 receptors (Mitchelson 1988), we have reevaluated this finding using a larger number of selective antagonists. The affinity values obtained in uteri from immature guinea-pigs were compared to those

^{*} This work has been presented in part at the Spring Meeting of the German Society for Pharmacology and Toxicology in Mainz, March 1990 (Dörje et al. 1990)

^{**} Present address: Laboratory of Molecular Biology, NINDS, NIH, Bld. 36, Rm. 3D-02, Bethesda MD 20892, USA

obtained at M_1 receptors in rabbit vas deferens, M_2 receptors in guinea-pig atria and smooth muscle M_3 receptors in guinea-pig ileum. Our data are not consistent with the presence of an M_1 , M_2 or M_3 receptor in the guinea-pig uterus but suggest that the pharmacology of the uterine muscarinic receptor is most closely related to that present in NG108-15 cells (Michel et al. 1989) and rat striatum (McKinney et al. 1989; Waelbroeck et al. 1990), which is considered the pharmacological correlate (M_4 receptor) of the m4 gene product.

Methods

Guinea-pig isolated uterus. Immature guinea-pigs (Pirbright-white, 190-220 g, 3-4 weeks old) were killed by a blow on the head and uterine horns were excised and separated from fat deposits and mesenteric attachments. Uterine horns were suspended under 1.0 g tension in 7 ml tissue baths containing oxygenated (95% $O_2 + 5\%$ CO₂) Sund's physiological salt solution (mmol/l: NaCl 154.0, KCl 5.63, CaCl₂ 0.54, MgCl₂ 0.95, NaHCO₃ 5.95, (+)-glucose 2.78). The preparations were maintained at 30°C and after 1 h equilibration period, isotonic contractions to carbachol were recorded by a forcedisplacement transducer connected to a Hellige amplifier and a Rikadenki multichannel recorder. Initially, the tissues were exposed to a single concentration of carbachol (3 µmol/l) to check the responsiveness to the agonist. Then two cumulative concentration-response curves to carbachol were constructed, one in the absence and one in the presence of antagonist. In separate control experiments, no significant changes in tissue sensitivity to the agonist was observed over the period necessary for the determination of two concentration-response curves.

Rabbit isolated vas deferens. Experiments on rabbit isolated vas deferens were performed according to Eltze (1988). Male New Zealand white rabbits (2.5-3.0 kg) were killed by i.v. injection of 120 mg/kg pentobarbitone sodium. Vasa deferentia were excised and divided into four segments of approximately 1.5 cm length. The preparations were set up in 7 ml organ baths containing modified Krebs buffer which consisted of (mmol/l): NaCl 118.0, KCl 4.7, CaCl₂ 1.8, MgSO₄ 0.6, KH₂PO₄ 1.2, NaHCO₃ 25.0 and (+)-glucose 11.1; 1 μ mol/l yohimbine was included to block α_2 -adrenoceptors. The bathing fluid was maintained at 31°C and aerated with 95% $O_2 + 5\%$ CO₂. A basal tension of 750 mg was applied. After a 30 min equilibration period twitch contractions were elicited by field stimulation (0.05 Hz, 0.5 ms, 30 V) with platinum electrodes and recorded as described for the isolated uterus. The neurogenic twitch contractions were concentration-dependently inhibited by the M1 receptor agonist 4-Cl-McN-A-343 [4-(4-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium iodide] (Eltze et al. 1988). After 1 h equilibration period, concentration-response curves were constructed by adding doses of 4-Cl-McN-A-343 cumulatively. When these responses were constant, concentration-response curves were repeated in the presence of antagonists.

Guinea-pig isolated atria and ileum. Guinea-pigs (Pirbright-white, 300-400 g) of either sex were killed by cervical dislocation. Left atria and ileal longitudinal muscle strips (Paton and Zar 1968) were set up in 6 ml organ baths, under 500 mg tension, in oxygenated (95% $O_2 + 5\%$ CO₂) Tyrode solution (32°C) composed of (mmol/ 1): NaCl 137.0, KCl 2.7, CaCl₂ 1.8, MgCl₂ 1.05, NaHCO₃ 11.9, NaH₂PO₄ 0.42 and (+)-glucose 5.6. Arccaidine propargyl ester (Moser et al. 1989) was used as an agonist. Atria were paced electrically (2 Hz, 3 ms, 5 V) by means of platinum electrodes. Negative inotropic effects to the agonist were measured as changes in isometric tension. Responses of ileal longitudinal muscle to arecaidine propargyl ester were measured as isotonic contractions. Atrial and ileal responses were recorded as with the isolated uterus. After an 1 h equilibration period, concentration-response curves to arecaidine

propargyl ester were obtained by use of cumulative dosing. When two control curves were superimposable, cumulative concentration-response curves were repeated in the presence of antagonists.

Antagonist affinities. Three to four different concentrations of each antagonist (log conc. intervals = 0.5) were used. Antagonists were allowed to equilibrate for 15-30 min (ileum and uterus), 30-45 min (atria) or 30-60 min in vas deferens, respectively. Preliminary experiments indicated that these intervals were sufficient for equilibration of the antagonist concentrations used. The uterus preparation was exposed to only one concentration of antagonist. EC₅₀-values of agonists in the absence and presence of antagonist were determined graphically for calculation of dose-ratios. The slopes of Arunlakshana-Schild plots (Arunlakshana and Schild 1959) were determined by linear regression by the method of least squares. pA₂-values were estimated as the intercept on the abscissa scale by fitting to the data the best straight line with a slope of unity (Tallarida and Murray 1986).

Statistical evaluation. The data are presented as means \pm SEM of *n* experiments. Differences between mean values were tested for statistical significance by Student's *t*-test; p < 0.05 was accepted as being significant.

Drugs. The following drugs were used: carbamoylcholine chloride, tetrodotoxin and yohimbine hydrochloride (Sigma, München, FRG); hexamethonium bromide (Fluka, Buchs, Switzerland); pirenzepine dihydrochloride and AF-DX 116 (11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3b][1,4]benzodiazepin-6-one)(Thomae, Biberach, FRG); himbacine hydrochloride (kindly donated by Dr. W. C. Taylor, Sydney, Australia); methoctramine tetrahydrochloride (generous gift from Dr. C. Melchiorre, Bologna, Italy); 4-DAMP (4-diphenylacetoxy-Nmethylpiperidine methiodide) (kindly donated by Dr. R. B. Barlow, Bristol, UK); sila-hexocyclium methyl sulfate (Tacke et al. 1989), 4-(4-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium iodide (4-Cl-McN-A343) (Nelson et al. 1976) and arecaidine propargyl ester (Mutschler and Hultzsch 1973) were synthesized in our laboratories. All other chemicals were of reagent grade and used as purchased.

Results

The contractile responses of the isolated guinea-pig uterus to carbachol were not significantly (P > 0.05) affected by the presence of tetrodotoxin (1 µmol/l) or hexamethonium (10 µmol/l), excluding the involvement of neuronal nicotinic or muscarinic receptors (data not shown).

All antagonists employed concentration-dependently inhibited the carbachol-induced contractile responses of the isolated guinea-pig uterus ($-\log EC_{50} = 5.73 \pm 0.03$) (Fig. 1) as well as the negative inotropic responses in guinea-pig atria ($-\log EC_{50} = 8.12 \pm 0.07$) and ileal contractions ($-\log EC_{50} = 7.77 \pm 0.04$) to arecaidine propargyl ester. Likewise, the 4-Cl-McN-A-343-induced inhibition of twitch contractions of the rabbit vas deferens ($-\log EC_{50} = 7.12 \pm 0.06$) was concentrationdependently blocked by all antagonists examined. In all tissues, parallel shifts of the agonist concentration-response curves without any appreciable changes of basal tension or reduction of maximum responses were observed. This is shown for pirenzepine, methoctramine and




Fig. 1. Cumulative concentration-response curves for carbacholinduced contractions of the guinea-pig uterus in the absence (\bigcirc) and presence (\bigcirc) of increasing concentrations of pirenzepine, methoctramine and sila-hexocyclium. Numbers next to the concentration-response curves indicate $-\log$ molar antagonist concentrations. Contractile responses to each concentration of agonist are expressed as a percentage of the maximum contraction induced by carbachol. The data points represent mean of n=3-5 observations (SEM are given as vertical bars if larger than symbol size)

sila-hexocyclium in Fig. 1. Arunlakshana-Schild plots were linear through the concentration range tested for each antagonist and slopes were not significantly different from unity (p > 0.05) (Table 1). Thus, all compounds behaved as competitive muscarinic antagonists in all preparations used. The pA₂-values determined for the various antagonists are shown in Table 1. As indicated, some data are taken from work previously published (Lambrecht et al. 1989; Waelbroeck et al. 1989). A comparison of pA₂values reveals that the antagonist affinities obtained at uterine muscarinic receptors of the guinea-pig do not correlate well with those determined at M_1 , M_2 or M_3 receptors (Table 1, Fig. 2A-C).

Discussion

Receptor binding studies suggest that smooth muscle of the ileum (Giraldo et al. 1988), urinary bladder (Monferini et al. 1988) and trachea (Roffel et al. 1989) have both M_2 and M_3 receptors. Functionally, however, smooth muscle contraction appears to be mediated through M_3 receptors only (Mitchelson 1988). In contrast to these reports, Eglen et al. (1989) suggested that the muscarinic receptor mediating smooth muscle contraction of the guinea-pig uterus is of the M_2 type. We have reevaluated this controversial finding using a larger number of selective antagonists. The affinities obtained at uterine muscarinic receptors of immature guinea-pigs were compared to those determined at M_1 (rabbit vas deferens), M_2 (guinea-pig atria) and M_3 receptors (guinea-pig ileum).

The antimuscarinic potencies of the antagonists at M_1 , M_2 and M_3 receptors (pA₂-values, Table 1) were in good agreement with their affinity estimates determined in radioligand binding studies (Lazareno and Roberts 1989; Waelbroeck et al. 1989) and previous functional studies (Barlow et al. 1976; Gilani and Cobbin 1986; Micheletti et al. 1987; Eltze 1988; Eltze et al. 1988; Waelbroeck et al. 1989; Lambrecht et al. 1989). A comparison of these affinity values with those determined at uterine muscarinic receptors suggests that the muscarinic receptor mediating contractions of the guinea-pig uterus is pharmacologically unique (Table 1). As discussed below, its profile is not consistent with the presence of an M₁, M₂ or M₃ receptor in this tissue. Moreover, since the slopes of Arunlakshana-Schild regression lines did not significantly differ from unity, the presence of a heterogeneous mixture of these subtypes appears to be unlikely (Table 1). This conclusion is further supported by radioligand binding studies which have identified a homogeneous population of muscarinic binding sites in the guinea-pig uterus (Eglen et al. 1989).

The affinity of pirenzepine $(pA_2 = 7.04)$ for uterine muscarinic receptors was 16-fold lower than that observed at M₁ receptors in vas deferens, excluding the presence of M₁ receptors (Table 1, Fig. 2A). Furthermore, uterine muscarinic receptors displayed high affinity for AF-DX 116 ($pA_2 = 6.96$), himbacine ($pA_2 = 7.92$) and methoctramine $(pA_2 = 7.52)$. Their pA_2 -values closely approached those obtained in guinea-pig atria (Fig. 2B) but were 3-, 4- and 24-fold higher, respectively, than observed at ileal M₃ receptors (Fig. 2C). These data, in conjunction with the low affinity found for pirenzepine, would indicate a high similarity of the uterine receptors to cardiac M2 receptors. However, the high antimuscarinic potencies of the selective antagonists 4-DAMP ($pA_2 = 8.87$) and sila-hexocyclium ($pA_2 = 8.81$) do not fit into this concept. These antagonists show a 3and 17-fold higher affinity for muscarinic receptors in the uterus than for atrial M₂ receptors (Fig. 2B).

Compound	Rabbit vas deferens (M ₁)	Guinea-pig atria (M ₂)	Guinea-pig ileum (M ₃)	Guinea-pig uterus
Pirenzepine	8.24 ± 0.06* (1.19 ± 0.10)	6.82 ± 0.03* (0.98 ± 0.02)	6.88 ± 0.04* (1.07 ± 0.04)	$7.04 \pm 0.02 (1.00 \pm 0.03) [n = 14; 14]$
AF-DX 116	7.12 ± 0.04 (1.07 ± 0.08) [<i>n</i> = 8; 4]	7.36 ± 0.05 (0.89 ± 0.08) [$n = 8; 8$]	$6.48 \pm 0.04 (0.93 \pm 0.07) [n = 10; 9]$	6.96 ± 0.03 (0.92 ± 0.05) [$n = 12; 12$]
Himbacine	8.17 ± 0.04 (1.02 ± 0.06) [n = 13; 7]	8.09 ± 0.04 (0.86 ± 0.07) [n = 8; 8]	$7.34 \pm 0.05 (0.93 \pm 0.08) [n = 8; 4]$	$7.92 \pm 0.03 (0.99 \pm 0.05) [n = 19; 19]$
Methoctramine	6.85 ± 0.07* (1.19 ± 0.10)	7.69 ± 0.03* (1.05 ± 0.05)	6.17 ± 0.05* (0.99 ± 0.09)	$7.51 \pm 0.03 (0.97 \pm 0.04) [n = 15; 15]$
4-DAMP	9.39 ± 0.06 (1.09 ± 0.12) [<i>n</i> = 8; 6]	8.40 ± 0.05 (0.93 ± 0.08) [n = 8; 8]	$9.34 \pm 0.05 (0.91 \pm 0.05) [n = 8; 8]$	8.87 ± 0.01 (1.01 ± 0.02) [n = 18; 18]
Sila-Hexocyclium	9.04 \pm 0.03 (1.07 \pm 0.06) [<i>n</i> = 8; 6]	7.57 ± 0.04** (0.94 ± 0.07)	8.78 ± 0.05** (1.04 ± 0.09)	$\begin{array}{l} 8.81 \pm 0.03 \\ (0.97 \pm 0.05) \\ [n = 16; 16] \end{array}$

Table 1. pA_2 -values and slopes of Arunlakshana-Schild plots (in parentheses) for various selective muscarinic antagonists at M_1 , M_2 , M_3 and guinea-pig uterine muscarinic receptors

The data are presented as means \pm SEM. The slopes of Arunlakshana-Schild plots were calculated by linear regression analysis (Tallarida and Murray 1986). pA₂-values were obtained after the unity constraint had been imposed. The number of total data points (n) and tissues used are given in square brackets. The slopes shown are not significantly different from unity (p > 0.05). * Data taken from Lambrecht et al. 1989; ** Data previously published (Waelbroeck et al. 1989)




Fig. 2A-D. Comparison of mean antagonist affinities (pA2-values, Table 1) obtained for pirenzepine (Pz), AF-DX 116, himbacine (Hi), methoctramine (Me), 4-DAMP and silahexocyclium (Sihc) at muscarinic receptors in guinea-pig uterus to their affinity estimates determined at M_1 (A), M_2 (B) and M_3 (C) receptors. Comparison of mean antagonist affinities (pA2- or pKi-values) obtained in functional studies in guinea-pig uterus and radioligand binding assays at M4 receptors present in rat striatum (Waelbroeck et al. 1990), (D). In case of receptor identity, the data points should not significantly deviate from the theoretical equality line (y = x). The distance to this line (given in Fig. 2A - Cfor pirenzepine, sila-hexocyclium and methoctramine as the antilog of the difference in pA2-values) is a direct measure of receptor selectivity

Taken together, the muscarinic receptors present in guinea-pig uterus display a novel pharmacological profile whose most characteristic features are a low affinity for pirenzepine but high affinity for methoctramine and silahexocyclium.

Recent findings suggest that the muscarinic receptors in rat striatum (McKinney et al. 1989; Waelbroeck et al. 1990) and NG108-15 cells (Michel et al. 1989; Baumgold and White 1989) are pharmacological equivalents (M_4 receptors) of the m4 gene (Brann et al. 1988; Peralta et al. 1987). In Fig. 2D, antagonist affinities (pA_2 -values) for muscarinic receptors in guinea-pig uterus are plotted against their binding affinities (pKi-values) for M4 receptors in rat striatum (Waelbroeck et al. 1990). Conspicuously, the affinity estimates of the antagonists obtained in guinea-pig uterus and rat striatum were strikingly similar. In addition, the binding affinities of pirenzepine, AF-DX 116, methoctramine and 4-DAMP at M₄ receptors in NG108-15 cells (Michel et al. 1989) correlate well with their functional potencies in the guinea-pig uterus (this study).

Biochemical studies with NG108-15 cells (Harden et al. 1986) and cloned muscarinic receptors (Peralta et al. 1988; Ashkenazi et al. 1989) revealed that m4 receptors strongly inhibit adenylate cyclase. Moreover, m4 receptors have also been shown to mediate stimulation of phosphoinositide hydrolysis (Peralta et al. 1988; Ashkenazi et al. 1989). Both second messenger responses have been reported to occur upon muscarinic stimulation of the immature guinea-pig uterus (Leiber et al. 1984; Marc et al. 1986).

We therefore hypothesize that the isolated guinea-pig uterus preparation may serve as a simple functional assay system to study the pharmacology of M_4 receptors. To lend further support to this notion, molecular biological studies are underway to verify that m4 mRNA is in fact expressed in this tissue.

Acknowledgements. The authors would like to thank Mr. W. Kujath and Dr. U. Albus (Hoechst AG, Frankfurt/M., FRG) for helpful advice. We also appreciate the helpful comments on the manuscript contributed by Dr. J. Wess. The expert technical assistance of Mrs. M. Wagner-Röder is gratefully acknowledged. G. L., E. M. and R. T. thank the Fonds der Chemischen Industrie and the Deutsche Forschungsgemeinschaft for financial support. F. D. was supported by a Kékulé-scholarship from the Stiftung Stipendien-Fonds des Verbandes der Chemischen Industrie.

References

- Akiba I, Kubo T, Maeda A, Bujor J, Nakai J, Mishina M, Numa S (1988) Primary structure of porcine muscarinic acetylcholine receptor III and antagonist binding studies. FEBS Lett 235:257-261
- Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ (1989) Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. Trends Pharmacol Sci Suppl 10:16-22
- Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58
- Barlow RB, Berry KJ, Glenton PAM, Nikolaou NM, Soh KS (1976) A comparison of affinity constants for muscarinic-sensitive acetylcholine receptors in guinea-pig atrial pacemaker cells at

 $29^{\circ}\mathrm{C}$ and in ileum at $29^{\circ}\mathrm{C}$ and $37^{\circ}\mathrm{C}.$ Br J Pharmacol 58:613-620

- Baumgold J, White TH (1989) Pharmacological differences between muscarinic receptors coupled to phosphoinositide turnover and those coupled to adenylate cyclase inhibition. Biochem Pharmacol 38:1605-1616
- Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527-532
- Bonner TI, Young AC, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403-410
- Brann MR, Buckley NJ, Bonner TI (1988) The striatum and cerebral cortex express different muscarinic receptor mRNAs. FEBS Lett 230:90-94
- Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989) Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35:469-476
- Doods HN, Mathy M-J, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA (1987) Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M₁, M₂ and M₃ receptors. J Pharmacol Exp Ther 242:257-262
- Dörje F, Friebe T, Tacke R, Mutschler E, Lambrecht G (1990) Pharmacological characterization of muscarinic receptors mediating contractions of guinea-pig uterus. Naunyn-Schmiedeberg's Arch Pharmacol 341: Suppl. R79 (abstract)
- Eglen RM, Michel AD, Whiting RL (1989) Characterisation of the muscarinic receptor subtype mediating contractions of the guinea-pig uterus. Br J Pharmacol 96:497-499
- Eltze M (1988) Muscarinic M1- and M2-receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens. Eur J Pharmacol 151:205-221
- Eltze M, Gmelin G, Wess J, Strohmann C, Tacke R, Mutschler E, Lambrecht G (1988) Presynaptic muscarinic receptors mediating inhibition of neurogenic contraction in rabbit vas deferens are of the ganglionic M₁-type. Eur J Pharmacol 158:233-242
- Gilani SAH, Cobbin LB (1986) The cardio-selectivity of himbacine: a muscarinic receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 332:16-20
- Giraldo E, Vigano MA, Hammer R, Ladinsky H (1988) Characterization of muscarinic receptors in guinea-pig ileum longitudinal smooth muscle. Mol Pharmacol 33:617-625
- Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980) Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90-92
- Hammer R, Giachetti A (1982) Muscarinic receptor subtypes: M1 and M2, biochemical and functional characterization. Life Sci 31:2991-2998
- Hammer R, Giraldo E, Schiavi GB, Montagna E, Ladinsky H (1986) Binding profile of a novel cardioselective muscarinic receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci 38:1653-1662
- Harden TK, Tanner LI, Martin MW, Nakahata N, Hughes AR, Helper JR, Evans T, Masters SB, Brown JH (1986) Characteristics of two biochemical responses to stimulation of muscarinic cholinergic receptors. Trends Pharmacol Sci Suppl. 7:14-18
- Lambrecht G, Feifel R, Wagner-Röder M, Strohmann C, Zilch H, Tacke R, Waelbroeck M, Christophe J, Boddeke H, Mutschler E (1989) Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol 168:71-80
- Lazareno S, Roberts FF (1989) Functional and binding studies with muscarinic M₂-subtype selective antagonists. Br J Pharmacol 98:309-317
- Leiber D, Harbon S, Guillet J-G, André C, Strosberg AD (1984) Monoclonal antibodies to purified muscarinic receptor display agonist-like activity. Proc Natl Acad Sci USA 81:4331-4334
- Levine RR, Birdsall NJM (eds) (1989) Subtypes of muscarinic receptors IV. Trends Pharmacol Sci Suppl 10:1-119
- Marc S, Leiber D, Harbon S (1986) Carbachol and oxytocin stimulate the generation of inositol phosphates in the guinea-pig myometrium. FEBS Lett 201:9-14

- McKinney M, Anderson D, Forray C, El-Fakahany EE (1989) Characterisation of the striatal M_2 muscarinic receptor mediating inhibition of cyclic AMP using selective antagonists: a comparison with the brainstem M_2 receptor. J Pharmacol Exp Ther 250: 565-572
- Melchiorre C, Angeli P, Lambrecht G, Mutschler E, Picchio MT, Wess J (1987) Antimuscarinic action of methoctramine, a new cardioselective M₂ muscarinic antagonist alone and in combination with atropine and gallamine. Eur J Pharmacol 144:117-124
- Micheletti R, Montagna E, Giachetti A (1987) AF-DX 116, a cardioselective muscarinic antagonist. J Pharmacol Exp Ther 241:628-634
- Michel AD, Delmondo R, Stefanich E, Whiting RL (1989) Binding characteristics of the muscarinic receptor subtype of the NG 108-15 cell line. Naunyn-Schmiedeberg's Arch Pharmacol 340:62-67
- Mitchelson F (1988) Muscarinic receptor differentiation. Pharmacol Ther 37:357-423
- Monferini E, Giraldo E, Ladinsky H (1988) Characterization of the muscarinic receptor subtypes in the rat urinary bladder. Eur J Pharmacol 147:453-458
- Moser U, Lambrecht G, Wagner M, Wess J, Mutschler E (1989) Structure-activity relationship of new analogues of arecaidine propargyl ester at muscarinic M₁ and M₂ receptor subtypes. Br J Pharmacol 96:319-324
- Mutschler E, Hultzsch K (1973) Über Struktur-Wirkungs-Beziehungen von ungesättigten Estern des Arecaidins und Dihydroarecaidins. Arzneimittelforschung 23:732-737
- Mutschler E, Lambrecht G (1984) Selective muscarinic agonists and antagonists in functional tests. Trends Pharmacol Sci Suppl 5:39-44
- Nelson WL, Freeman DS, Vinzenzi FF (1976) Stereochemical analogs of a muscarinic, ganglionic stimulant, 2. Cis and trans

- Paton WDM, Zar MA (1968) The origin of acetylcholine release from guinea-pig intestine and longitudinal muscle strips. J Physiol 194:13-33
- Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 6:3923-3929
- Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ (1988) Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 334:434-437
- Roffel AF, Elzinga CRS, Meurs H, Zaagsma J (1989) Allosteric interactions of three muscarinic antagonists at bovine tracheal smooth muscle and cardiac M₂ receptors. Eur J Pharmacol – Mol Pharmacol Sect 172:61-70
- Tacke R, Linoh H, Rafeiner K, Lambrecht G, Mutschler E (1989) Synthesis and properties of the selective antimuscarinic agent sila-hexocyclium methyl sulfate. J Organomet Chem 359:159-168
- Tallarida RJ, Murray RB (1986) Manual of pharmacologic calculations with computer programs. Sec ed, Springer, Berlin Heidelberg New York Tokyo
- Waelbroeck M, Tastenoy M, Camus J, Christophe J, Strohmann C, Linoh H, Zilch H, Tacke R, Mutschler E, Lambrecht G (1989) Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/ hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol 98:197-205
- Waelbroeck M, Camus J, Tastenoy M, Christophe J (1990) Identification of the striatum "B" sites as belonging to the M4 muscarinic receptor subtype. Naunyn-Schmiedeberg's Arch Pharmacol 341:Suppl. R80 (abstract)